Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Alteration of bone sialoprotein expression in osseous metastasized renal cell carcinomas and the tumor surrounding tissue.

Mittag F, Hennenlotter J, Minkley L, Ipach I, Schilling D, Scharpf M, Stenzl A, Leichtle U, Kluba T.

Clin Exp Metastasis. 2012 Feb;29(2):179-83. doi: 10.1007/s10585-011-9441-5. Epub 2011 Dec 1.

PMID:
22130963
2.

Prognostic role of bone sialoprotein in clear cell renal carcinoma.

Righi L, Bollito E, Ceppi P, Mirabelli D, Tavaglione V, Chiusa L, Porpiglia F, Brunelli M, Martignoni G, Terrone C, Papotti M.

Anticancer Res. 2013 Jun;33(6):2679-87.

PMID:
23749927
3.

XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma.

Gakis G, Hennenlotter J, Scharpf M, Hevler J, Schilling D, Kuehs U, Stenzl A, Schwentner C.

World J Urol. 2011 Dec;29(6):801-6. doi: 10.1007/s00345-010-0621-8. Epub 2010 Nov 27.

PMID:
21113600
4.

Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels.

Horstmann M, Merseburger AS, von der Heyde E, Serth J, Wegener G, Mengel M, Feil G, Hennenlotter J, Nagele U, Anastasiadis A, Bokemeyer C, Stenzl A, Kuczyk M.

J Cancer Res Clin Oncol. 2005 Nov;131(11):715-22. Epub 2005 Nov 1.

PMID:
16080018
5.

Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.

Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G.

Clin Cancer Res. 1999 Dec;5(12):3914-9.

6.

Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers.

Waltregny D, Bellahcène A, de Leval X, Florkin B, Weidle U, Castronovo V.

J Bone Miner Res. 2000 May;15(5):834-43.

7.

Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.

Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA, Belldegrun AS.

Cancer. 2005 Jun 15;103(12):2517-25.

8.

Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study.

Papotti M, Kalebic T, Volante M, Chiusa L, Bacillo E, Cappia S, Lausi P, Novello S, Borasio P, Scagliotti GV.

J Clin Oncol. 2006 Oct 20;24(30):4818-24.

PMID:
17050866
9.

Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer.

Merseburger AS, Hennenlotter J, Simon P, Kruck S, Koch E, Horstmann M, Kuehs U, Küfer R, Stenzl A, Kuczyk MA.

Anticancer Res. 2005 May-Jun;25(3B):1901-7.

10.

Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression.

Kruck S, Bedke J, Hennenlotter J, Ohneseit PA, Kuehs U, Senger E, Sievert KD, Stenzl A.

Oncol Rep. 2010 Jan;23(1):159-63.

PMID:
19956876
11.

Expression of bone sialoprotein and osteopontin in breast cancer bone metastases.

Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J, Tenenbaum HC, Ganss B, Cheifetz S.

Clin Exp Metastasis. 2000;18(3):253-60.

PMID:
11315099
12.

Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia.

Tickoo SK, dePeralta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, Moch H, Amin MB.

Am J Surg Pathol. 2006 Feb;30(2):141-53.

PMID:
16434887
13.

Prognostic factors and analysis of S100a4 protein in resected pulmonary metastases from renal cell carcinoma.

Bandiera A, Melloni G, Freschi M, Giovanardi M, Carretta A, Borri A, Ciriaco P, Zannini P.

World J Surg. 2009 Jul;33(7):1414-20. doi: 10.1007/s00268-009-0023-5.

PMID:
19365673
14.

Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?

Tölle A, Jung M, Lein M, Johannsen M, Miller K, Moch H, Jung K, Kristiansen G.

BMC Cancer. 2009 Jul 21;9:248. doi: 10.1186/1471-2407-9-248.

15.

Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha.

Lidgren A, Bergh A, Grankvist K, Rasmuson T, Ljungberg B.

BJU Int. 2008 Feb;101(4):480-4. Epub 2007 Oct 8.

16.

Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray.

Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Bergh A, Ljungberg B.

Eur Urol. 2006 Dec;50(6):1272-7. Epub 2006 Jun 13.

PMID:
16814458
17.

Tissue expression and plasma levels of adrenomedullin in renal cancer patients.

Michelsen J, Thiesson H, Walter S, Ottosen PD, Skøtt O, Jensen BL.

Clin Sci (Lond). 2006 Jul;111(1):61-70.

PMID:
16515534
18.

Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.

Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED.

Cancer. 2005 Nov 15;104(10):2084-91.

19.
20.

The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma.

Kankuri M, Söderström KO, Pelliniemi TT, Vahlberg T, Pyrhönen S, Salminen E.

Anticancer Res. 2006 Sep-Oct;26(5B):3825-33.

Supplemental Content

Support Center